Acute PainPhase 2NCT05317312
Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
A Phase 2 study testing MR-107A-02 in people with Acute Pain and Post Operative Pain, run by Mylan Specialty, LP at 1 site in United States.
Trial summary
MR-107A-02 is being studied to investigate its efficacy, safety and dose-response after dental surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Pain, Post Operative Pain, Pain
- What is being tested?
- MR-107A-02
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 111 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Mar 2022to 20 Jun 2022
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males and females ≥18 years of age.
- Requirement for dental surgery for extraction of ≥2 third molars, at least 1 of which involves partial or complete mandibular bony impaction.
- Pain Intensity (PI) using a Numeric Pain Rating Scale (NPRS) ≥5 during the 5 hours following the end of surgery in the eligibility assessment as well as in the baseline assessment immediately pre-dosing.
- Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following the end of surgery.
Who cannot join
- Previously dosed with MR-107A-02.
- Subject with known hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs).
- Active GI bleeding or a history of peptic ulcer disease, active inflammatory bowel disease, e.g., Crohn's Disease or ulcerative colitis,or bleeding disorders that may affect coagulation.
- Moderate or severe hypertension, prior stroke or transient ischemic attack.
- Use of any investigational drug within 28 days, or 5 half-lives, prior to consent whichever is longer.
- Use of medications with the potential to interact with MR-107A-02.
- Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Response Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
MR-107A-02 is being studied to investigate its efficacy, safety and dose-response after dental surgery.
- Conditions
- Acute Pain, Post Operative Pain, Pain
- Being tested
- MR-107A-02, Placebo
- Medical subject headings
- Acute Pain, Pain, Postoperative, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MR-107A-02Drug
MR-107A-02 oral tablet
PlaceboDrug
Placebo oral tablet
| Study group | Role | What they receive |
|---|---|---|
| MR-107A-02 1.25 mg twice in a 24 hour period | Experimental | Oral tablet, one day of dosing Receives: Drug: MR-107A-02 |
| MR-107A-02 5 mg twice in a 24 hour period | Experimental | Oral tablet, one day of dosing Receives: Drug: MR-107A-02 |
| MR-107A-02 15 mg twice in a 24 hour period | Experimental | Oral tablet, one day of dosing Receives: Drug: MR-107A-02 |
| Placebo twice in a 24 hour period | Placebo comparator | Oral tablet, one day of dosing Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Summed Pain Intensity Difference (SPID)
Participants assessed Pain Intensity (PI) using a 0-10 numeric pain rating scale (NPRS) where 0 is no pain and 10 is worst pain imaginable. PI was assessed 18 times within 24 hours after the first study dose, and immediately before any rescue medication and/or at early termination. The participant's baseline PI was subtracted from the timepoint PI, to derive a Pain Intensity Difference (PID) for each timepoint. Overall Summed Pain Intensity Difference (SPID) measures pain intensity change relative to baseline over the 24 hour period after dosing, and corresponds to the Area Under the Curve (AUC) of the PID. In this study, higher positive Overall SPID indicates better pain improvement. Overall SPID could range from -120 to 240. Two hour windowed last observation carried forward was used as applicable where PI score obtained before a rescue medication replaced PI score for each timepoint within 2 hours following rescue dose.
Measured: 24 hours after the first dose
Secondary outcomes (5)
Pain Intensity Using a Number Pain Rating Scale Utilizing 6-hour Windowed Last Observation Carried Forward (W6LOCF)
10 point scale, where 0 is no pain and 10 is the worst pain imaginable; 6-hour windowed last observation carried forward (W6LOCF) utilizes "pain right now" just prior to rescue medication use and censors subsequent pain intensity values for 6 hours when calculating SPIDs
Measured: 24 hours after first dose
Time to Perceptible Pain Relief.
Measured by double stopwatch technique. The time to onset of first perceptible relief (time that the first watch is stopped) is defined as the postdose time at which the subject first begins to feel pain relief at their estimation.
Measured: 24 hours after first dose
Time to Meaningful Pain Relief
Measured by double stopwatch technique The time to meaningful pain relief (time that the second watch is stopped) is defined as the postdose time at which the subject begins to feel meaningful pain relief at their estimation
Measured: 24 hours after first dose
Patient's Global Assessment of Pain Control
5 point PGA (Patient's Global Assessment) of pain control scale, where 0 is poor, 1 is fair, 2 is good, 3 is very good, and 4 is excellent
Responder = 2 is good, 3 is very good, and 4 is excellent Non-responder = 1 is fair, 0 is poor, and missing values.
Measured: 24 hours
Rescue Medication Use
Percentage of subjects using rescue medication from 0-24 hours
Measured: 24 hours after first dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2022
- Study start31 Mar 2022
- Primary completion15 Jun 2022
- Study completion20 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 111 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mylan Specialty, LP
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05317312
- Sponsor's protocol ID
- MELO-TFZ-2001
- Status last verified
- Aug 2023
- First submitted
- 16 Mar 2022
- Last updated
- 7 Aug 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Bertoch TM, Grisham S, Vogt S, Haughie S, Ocasio K, Smith JP. A randomized, double-blind, placebo-controlled, parallel group, dose-response study of MR-107A-02 in the treatment of post-surgical dental pain. Pain Med. 2026 Nov 1;27(11):1185-1199. doi: 10.1093/pm/pnag095.
PubMed 42502959
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Response Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
- ClinicalTrials.gov ID
- NCT05317312
- Acronym / sponsor ID
- MELO-TFZ-2001
- Conditions
- Acute Pain, Post Operative Pain, Pain
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 111 participants (actual)
- Lead sponsor
- Mylan Specialty, LPIndustry (pharma, biotech, devices)
- Study start
- 31 Mar 2022 (actual)
- Primary completion
- 15 Jun 2022 (actual)
- Study completion
- 20 Jun 2022 (actual)
- First posted
- 7 Apr 2022 (actual)
- Results
- Posted 7 Aug 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
MR-107A-02 is being studied to investigate its efficacy, safety and dose-response after dental surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| MR-107A-02 1.25 mg twice in a 24 hour period | Experimental | Drug: MR-107A-02Oral tablet, one day of dosing |
| MR-107A-02 5 mg twice in a 24 hour period | Experimental | Drug: MR-107A-02Oral tablet, one day of dosing |
| MR-107A-02 15 mg twice in a 24 hour period | Experimental | Drug: MR-107A-02Oral tablet, one day of dosing |
| Placebo twice in a 24 hour period | Placebo comparator | Drug: PlaceboOral tablet, one day of dosing |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Males and females ≥18 years of age.
- Requirement for dental surgery for extraction of ≥2 third molars, at least 1 of which involves partial or complete mandibular bony impaction.
- Pain Intensity (PI) using a Numeric Pain Rating Scale (NPRS) ≥5 during the 5 hours following the end of surgery in the eligibility assessment as well as in the baseline assessment immediately pre-dosing.
- Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following the end of surgery.
Key exclusion criteria (7 listed)
- Previously dosed with MR-107A-02.
- Subject with known hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs).
- Active GI bleeding or a history of peptic ulcer disease, active inflammatory bowel disease, e.g., Crohn's Disease or ulcerative colitis,or bleeding disorders that may affect coagulation.
- Moderate or severe hypertension, prior stroke or transient ischemic attack.
- Use of any investigational drug within 28 days, or 5 half-lives, prior to consent whichever is longer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MR-107A-02MR-107A-02 oral tablet | Drug | MR-107A-02 1.25 mg twice in a 24 hour period, MR-107A-02 15 mg twice in a 24 hour period, MR-107A-02 5 mg twice in a 24 hour period |
| PlaceboPlacebo oral tablet | Drug | Placebo twice in a 24 hour period |
Primary outcome
Overall Summed Pain Intensity Difference (SPID)
Time frame: 24 hours after the first dose
Participants assessed Pain Intensity (PI) using a 0-10 numeric pain rating scale (NPRS) where 0 is no pain and 10 is worst pain imaginable. PI was assessed 18 times within 24 hours after the first study dose, and immediately before any rescue medication and/or at early termination. The participant's baseline PI was subtracted from the timepoint PI, to derive a Pain Intensity Difference (PID) for each timepoint. Overall Summed Pain Intensity Difference (SPID) measures pain intensity change relative to baseline over the 24 hour period after dosing, and corresponds to the Area Under the Curve (AUC) of the PID. In this study, higher positive Overall SPID indicates better pain improvement. Overall SPID could range from -120 to 240. Two hour windowed last observation carried forward was used as applicable where PI score obtained before a rescue medication replaced PI score for each timepoint within 2 hours following rescue dose.
5 secondary outcomes
Pain Intensity Using a Number Pain Rating Scale Utilizing 6-hour Windowed Last Observation Carried Forward (W6LOCF)
Time frame: 24 hours after first dose
Time to Perceptible Pain Relief.
Time frame: 24 hours after first dose
Time to Meaningful Pain Relief
Time frame: 24 hours after first dose
Patient's Global Assessment of Pain Control
Time frame: 24 hours
Rescue Medication Use
Time frame: 24 hours after first dose
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42502959Bertoch TM, Grisham S, Vogt S, Haughie S, Ocasio K, Smith JP. A randomized, double-blind, placebo-controlled, parallel group, dose-response study of MR-107A-02 in the treatment of post-surgical dental pain. Pain Med. 2026 Nov 1;27(11):1185-1199. doi: 10.1093/pm/pnag095.
Related trials for Acute Pain
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruitingPhase 2
A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)
Pain Management
Not yet recruitingPhase 2
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
Healthy Volunteers
Not yet recruiting
Post-operative Pain and Clinical Outcome After Single-cone Obturation With a Calcium Silicate-based Versus Epoxy Resin Sealer
Post Operative Pain, Acute, Irreversible Pulpitis (Toothache)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing MR-107A-02 in people with Acute Pain and Post Operative Pain, run by Mylan Specialty, LP at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Aug 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Summed Pain Intensity Difference (SPID) (time frame: 24 hours after the first dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05317312, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2023.